Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus
NCT06937203Phase 2Recruiting
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- May 2025
- Primary completion
- Feb 2027
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of ARO-ALK7 in obesity (4 arms), sponsored by Arrowhead Pharmaceuticals. Primary endpoint: Number of Participants with Treatment-Emergent Adverse Events. Started May 2025; status: recruiting.
02
Drugs
ARO-ALK7
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06937203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06937203.